Diabetes
Refine Search
Pharmaceutical
The US Food and Drug Administration on Monday approved Victoza (liraglutide) injection for the treatment of pediatric patients aged 10 years or older with type 2 diabetes, under a priority review evaluation. 18 June 2019
Biotechnology
Belgian immunotherapies developer Imcyse today announces that it has raised 35 million euros ($39.5 million) in a Series B financing round and through other channels. Imcyse is a spin-off from Belgium’s Katholieke Universiteit Leuven (KUL). 18 June 2019
Pharmaceutical
The Johnson & Johnson subsidiary Janssen has presented important results on Invokana (canagliflozin) at the American Diabetes Association (ADA) meeting. 12 June 2019
Biotechnology
Denmark’s Novo Nordisk has presented new safety data from the PIONEER 6 trial, testing its landmark oral formulation of the biologic semaglutide, compared with placebo, both in addition to standard of care. 12 June 2019
Pharmaceutical
Anglo-Swedish pharma major AstraZeneca has released new date from a pre-specified exploratory analysis of renal data from the Phase III DECLARE-TIMI 58 trial, the broadest cardiovascular outcomes trial of a sodium-glucose co-transporter 2 (SGLT2) inhibitor, showing that Farxiga (dapagliflozin) reduced the progression of kidney disease or renal death in patients with type-2 diabetes (T2D). 11 June 2019
Pharmaceutical
Geropharm, one of Russia’s top drugmakers, plans to become one of the leading producers and suppliers of insulin in the Latin American region in years to come. 11 June 2019
Pharmaceutical
Pharma major Sanofi has made presentations at the American Diabetes Association (ADA) meeting that reflect its latest progress in type 1 and 2 of the condition. 10 June 2019
Pharmaceutical
Data presented at the American Diabetes Association's (ADA) 79th Scientific Session on two Phase III studies show that Eli Lilly’s ultra rapid lispro (URLi) provided non-inferior A1C reductions compared to Humalog (insulin lispro) at 26 weeks in people with type 1 and type 2 diabetes. 10 June 2019
Biotechnology
Immune-mediated disease specialist Provention Bio has presented data from the At-Risk study, testing its type 1 diabetes candidate PRV-031 (teplizumab). 10 June 2019
Pharmaceutical
Findings presented Saturday from two Phase IIIa clinical trials evaluated oral semaglutide 14mg versus Jardiance (empagliflozin 25mg) in PIONEER 2 and oral semaglutide 14mg versus Victoza (liraglutide 1.8mg) in PIONEER 4 over 52 weeks in adults with type 2 diabetes (T2D). 10 June 2019
Pharmaceutical
In a surprise announcement, French pharma major Sanofi has revealed that chief executive Olivier Brandicourt will retire in September, to be replaced by Novartis’ current pharma chief, Paul Hudson. 7 June 2019
Pharmaceutical
The US Food and Drug Administration (FDA) has accepted the New Drug Application for the investigational fixed-dose combination tablet of empagliflozin, linagliptin and metformin extended release (XR) for the treatment of adults with type 2 diabetes. 4 June 2019
Pharmaceutical
The UK subsidiary of French drug major Sanofi today announced the launch of Toujeo (insulin glargine 300 units/mL) DoubleStar, a new long-acting insulin glargine injection pen recommended for adults with type 1 or type 2 diabetes mellitus, who require at least 20 units of basal insulin per day. 3 June 2019
Pharmaceutical
Japan’s Sumitomo Dainippon has signed a co-promotion and sales collaboration agreement with Swiss pharma giant Novartis, related to the type 2 diabetes drug Equa (vildagliptin). 31 May 2019
Pharmaceutical
Sino-American drug developer Anji Pharmaceuticals said yesterday that it has acquired global development rights for a novel delayed-release formulation of metformin (Metformin DR) with applications in diabetic patients. 30 May 2019
Pharmaceutical
Eli Lilly says that its previously-announced lower-priced Insulin Lispro Injection is now available for order in US pharmacies for people who use Lilly's rapid-acting insulin and need a lower-cost option. 22 May 2019
Biotechnology
The US Food and Drug Administration has approved Eylea (aflibercept) Injection to treat all stages of diabetic retinopathy (DR), and thereby reduce the risk of blindness, marking the fifth indication for the drug in the USA. 14 May 2019
Biosimilars
Ned Sharpless, Acting Commissioner of the US Food and Drug Administration, has issued a statement outlining final guidance aimed at helping bring interchangeable biosimilars to market. 13 May 2019
Biotechnology
A first-of-its-kind trial of oral insulin being spearheaded by Israeli diabetes specialist Oramed Pharmaceuticals is now taking place at 37 research centers across the USA. 9 May 2019
Biotechnology
A team of researchers led by Harvard University scientists has improved the laboratory process of converting stem cells into insulin-producing beta cells, using biological and physical separation methods to enrich the proportion of beta cells in a sample. 8 May 2019
Generics
Viatris has disclosed that its oral finished-dose manufacturing facility in Indore, India, is subject to regulatory action from the US regulator, after an inspection earlier this year. 24 December 2024
Generics
The US Food and Drug Administration (FDA) revealed on Monday that it has approved the first generic referencing Victoza (liraglutide injection) 18 milligram/3 milliliter. 24 December 2024
Pharmaceutical
US pharma major Eli Lilly has recently announced a £279 million ($365.5 million) investment in the UK at the International Investment Summit in London. 19 December 2024
Pharmaceutical
The Egyptian Drug Authority has approved EVA Pharma's insulin glargine injection, marking a significant milestone in its collaboration with US pharma major Eli Lilly. 18 December 2024
Pharmaceutical
The European Commission has approved unconditionally, under the EU Merger Regulation, the proposed acquisition of contract development and manufacture organization (CDMO) Catalent (NYSE: MCTLT) by Denmark’s Novo Holdings. 7 December 2024
Biotechnology
Novavax has agreed to sell its manufacturing plant in the Czech Republic to Novo Nordisk for $200 million. 6 December 2024
Pharmaceutical
Novo Nordisk will reduce the US list prices of two insulin products, Tresiba (insulin degludec) and Fiasp (insulin aspart), by over 70% from 2026. 6 December 2024
Pharmaceutical
Eli Lilly has announced a $3 billion investment to expand its recently acquired manufacturing facility in Wisconsin, USA. 6 December 2024
Pharmaceutical
Danish diabetes and obesity giant Novo Nordisk has announced plans to invest 2.9 billion Danish kroner ($410 million) to establish a cutting-edge quality control laboratory in Hillerød, Denmark. 6 December 2024
Biotechnology
Dutch privately held Amarna Therapeutics, which specializes in transformative gene therapies, has entered into a strategic collaboration with Sweden-based NorthX Biologics, a leading biologics manufacturing partner. 4 December 2024
Pharmaceutical
The China-based subsidiary of French pharma major Sanofi revealed it has signed a memorandum of cooperation with Beijing Municipal Bureau of Economy and Information Technology and Beijing Economic and Technological Development Zone today to invest approximately 1 billion euros ($1.05 billion) to establish a new manufacturing base. 3 December 2024
Pharmaceutical
Hua Medicine has announced promising new clinical findings for its glucokinase activator dorzagliatin, presented at the China BioMed Innovation and Investment Conference. 2 December 2024
Pharmaceutical
Australia’s Department of Health and Aged Care has developed a new API (application programming interface) for the efficient distribution of the monthly Pharmaceutical Benefits Scheme (PBS) schedule data. 2 December 2024
Biotechnology
Privately-held UK firm Quell Therapeutics, which positions itself as a pioneer in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, has announced that AstraZeneca has selected a candidate to progress in the type 1 diabetes (T1D) Treg cell therapy program. 18 November 2024
Pharmaceutical
French pharma major Sanofi today announced an investment of 40 million euros ($42.4 million) in its Lyon Gerland bioproduction site, consolidating its role as a strategic platform dedicated to immunology. 15 November 2024
Pharmaceutical
Privately-held Montanan firm Microbion has announced promising findings from its Phase II study of pravibismane, a topical treatment aimed at addressing diabetic foot ulcer infections (DFI). 14 November 2024
Pharmaceutical
While sky high expectations for Eli Lilly’s tirzepatide have not yet been realized, more positive data add to a growing sense that the future could be as bright as imagined. 14 November 2024
Pharmaceutical
Germany’s Merck KGaA was trading 5% lower as Thursday’s trading day neared its end, after the company announced its third-quarter financial results and outlook for the rest of the year. 14 November 2024
Pharmaceutical
Anglo-Swedish drugmaker AstraZeneca beat analyst expectations with its third-quarter 2024 revenue and earnings figures. 12 November 2024
Biotechnology
French biotech DiogenX, which is focused on regenerating insulin-producing beta cells for the treatment of diabetes, today announces the appointment of Dr Klara Owen as chief medical officer. 12 November 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze